Lucid Diagnostics Inc.
$1.46
0.1 (7.35%)
LUCD Price Chart
| Basic | |
|---|---|
| Market Cap | $86.64M |
| Price | $1.46 |
| 52 Week Range | 0.63-1.51 |
| Beta | 1.49 |
| Margins | |
| Gross Profit Margin | -80.14% |
| Operating Profit Margin | -1059.66% |
| Net Profit Margin | -1047.61% |
| Valuation (TTM) | |
| P/E Ratio | -1.60 |
| Price to Sales Ratio | 19.66 |
| Price to Book Ratio | 13.49 |
| PEG Ratio | -0.52 |
Industry
Medical - Devices
Sector
Healthcare
Full-Time Employees
70
Website
IPO Date
2021-10-14T00:00:00.000Z
Description
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Phone
212 949 4319
Address
One Grand Central Place, New York, NY, 10165, US
CIK
0001799011